Autres langues Exelixis, Inc.

Actions

EXEL

US30161Q1040

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 18:35:40 10/08/2026			Varia. 5j.	Varia. 1 janv.
52,82 ^USD	-2,30%		-4,40%	+20,09%

06/08	Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026
05/08	(EXEL) Exelixis anticipe désormais un chiffre d'affaires pour l'exercice 2026 entre 2,50 et 2,55 milliards de dollars, contre une estimation FactSet de 2,60 milliards de dollars	MT

Autres langues

05/08	(EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B
05/08	Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M
05/08	Earnings Flash (EXEL) Exelixis Posts Q2 Revenue $628.7M, vs. FactSet Est of $636.4M
05/08	Exelixis Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours
05/08	Exelixis: Q2 Earnings Snapshot
05/08	Exelixis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (EXEL) Exelixis, Inc. Posts Q2 Adjusted EPS $0.91 per Share, vs. FactSet Est of $0.85
05/08	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
05/08	Exelixis, Inc. Updates Earnings Guidance for Fiscal Year 2026
23/07	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
22/07	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says
02/07	Afternoon Meeting: Wall Street celebra la debilidad
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Value-Defensive Index
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Growth-Defensive Index
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index
22/06	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
22/06	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
01/06	Wall Street comienza junio en tensión
01/06	Wall Street startet nervös in den Juni
01/06	Wall Street Starts June on Edge
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026